These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16919740)

  • 1. Naltrexone as negative reinforcement comments on "A behavioral analysis of coerced treatment for addicted offenders".
    Farabee D
    J Subst Abuse Treat; 2006 Sep; 31(2):141-2. PubMed ID: 16919740
    [No Abstract]   [Full Text] [Related]  

  • 2. Depot naltrexone in lieu of incarceration: a behavioral analysis of coerced treatment for addicted offenders.
    Marlowe DB
    J Subst Abuse Treat; 2006 Sep; 31(2):131-9. PubMed ID: 16919739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of depot naltrexone under legal coercion: the case for caution.
    Hall W; Capps B; Carter A
    Addiction; 2008 Dec; 103(12):1922-4. PubMed ID: 19469728
    [No Abstract]   [Full Text] [Related]  

  • 4. Naltrexone as a "mandate" or as a choice comments on "Judicially mandated naltrexone use by criminal offenders: a legal analysis".
    Presenza LJ
    J Subst Abuse Treat; 2006 Sep; 31(2):129-30. PubMed ID: 16919738
    [No Abstract]   [Full Text] [Related]  

  • 5. Health for life. Addiction: how to break the chain.
    Miller MC
    Newsweek; 2005 Dec; 146(24):58. PubMed ID: 16375164
    [No Abstract]   [Full Text] [Related]  

  • 6. Judicially mandated naltrexone use by criminal offenders: a legal analysis.
    Bonnie RJ
    J Subst Abuse Treat; 2006 Sep; 31(2):121-7. PubMed ID: 16919737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners.
    Kaur M; Liguori A; Lang W; Rapp SR; Fleischer AB; Feldman SR
    J Am Acad Dermatol; 2006 Apr; 54(4):709-11. PubMed ID: 16546596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome.
    Grant JE; Odlaug BL; Potenza MN
    Harv Rev Psychiatry; 2007; 15(2):80-5. PubMed ID: 17454177
    [No Abstract]   [Full Text] [Related]  

  • 9. Getting beyond the research clinic studies: comments on Morris et al. (2001).
    O'Malley SS
    Addiction; 2001 Dec; 96(12):1859-60. PubMed ID: 11791533
    [No Abstract]   [Full Text] [Related]  

  • 10. Internet sex addiction treated with naltrexone.
    Bostwick JM; Bucci JA
    Mayo Clin Proc; 2008 Feb; 83(2):226-30. PubMed ID: 18241634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of obsessive-compulsive cutting behavior with naltrexone.
    Bystritsky A; Strausser BP
    J Clin Psychiatry; 1996 Sep; 57(9):423-4. PubMed ID: 9746454
    [No Abstract]   [Full Text] [Related]  

  • 12. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
    Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
    Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alcohol dependence. Behavior therapy is effective with naltrexone].
    Schmitt-Hönl B
    Med Monatsschr Pharm; 2006 Oct; 29(10):380-1. PubMed ID: 17058899
    [No Abstract]   [Full Text] [Related]  

  • 14. Naltrexone for lipodystrophy.
    AIDS Patient Care STDS; 2000 May; 14(5):283. PubMed ID: 10833818
    [No Abstract]   [Full Text] [Related]  

  • 15. Naltrexone for the treatment of obesity: review and update.
    Lee MW; Fujioka K
    Expert Opin Pharmacother; 2009 Aug; 10(11):1841-5. PubMed ID: 19537999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone.
    Gade K; Häussinger C; Bandelow B
    Pharmacopsychiatry; 2009 Jul; 42(4):164-5. PubMed ID: 19585396
    [No Abstract]   [Full Text] [Related]  

  • 17. The social implications of neurobiological explanations of resistible compulsions.
    Carter A; Hall W
    Am J Bioeth; 2007 Jan; 7(1):15-7. PubMed ID: 17366154
    [No Abstract]   [Full Text] [Related]  

  • 18. Regarding naltrexone for probationers and parolees.
    Stancliff S
    J Subst Abuse Treat; 2007 Mar; 32(2):217-8; author reply 218-9. PubMed ID: 17306730
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming opioid blockade from depot naltrexone (Prodetoxon).
    Kruptisky EM; Burakov AM; Tsoy MV; Egorova VY; Slavina TY; Grinenko AY; Zvartau EE; Woody GE
    Addiction; 2007 Jul; 102(7):1164-5. PubMed ID: 17498182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.
    Mitchell JM; Fields HL; White RL; Meadoff TM; Joslyn G; Rowbotham MC
    J Clin Psychopharmacol; 2007 Feb; 27(1):112-5. PubMed ID: 17224736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.